These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 27312161)
1. Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia? Schifferli A; Kühne T Semin Hematol; 2016 Apr; 53 Suppl 1():S31-4. PubMed ID: 27312161 [TBL] [Abstract][Full Text] [Related]
2. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973 [TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis. Tumaini Massaro J; Chen Y; Ke Z Platelets; 2019; 30(7):828-835. PubMed ID: 30810479 [TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Kühne T; Imbach P Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Liebman HA; Pullarkat V Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062 [TBL] [Abstract][Full Text] [Related]
9. A United Kingdom Immune Thrombocytopenia (ITP) Forum review of practice: thrombopoietin receptor agonists. Thachil J; Bagot C; Bradbury C; Cooper N; Lester W; Grainger JD; Lowe G; Evans G; Talks K; Sibson K; Garg M; Murphy MF; Watson HG; Bolton-Maggs PHB; Watson S; Scully M; Provan D; Newland A; Hill QA Br J Haematol; 2018 Feb; 180(4):591-594. PubMed ID: 27879997 [No Abstract] [Full Text] [Related]
10. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524 [TBL] [Abstract][Full Text] [Related]
11. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824 [TBL] [Abstract][Full Text] [Related]
12. Current Management of Primary Immune Thrombocytopenia. Provan D; Newland AC Adv Ther; 2015 Oct; 32(10):875-87. PubMed ID: 26499177 [TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review. Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713 [TBL] [Abstract][Full Text] [Related]
14. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Gernsheimer TB Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086 [TBL] [Abstract][Full Text] [Related]
15. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Kuter DJ Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568 [TBL] [Abstract][Full Text] [Related]
16. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Rodeghiero F; Carli G Ann Hematol; 2017 Sep; 96(9):1421-1434. PubMed ID: 28275823 [TBL] [Abstract][Full Text] [Related]
17. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Mitchell WB; Pinheiro MP; Boulad N; Kaplan D; Edison MN; Psaila B; Karpoff M; White MJ; Josefsson EC; Kile BT; Bussel JB Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654 [TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres. Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125 [TBL] [Abstract][Full Text] [Related]
19. Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura. Bal G; Fabian D; Maia D; Ringel F; Salama A Ann Hematol; 2017 Dec; 96(12):2045-2056. PubMed ID: 28965224 [TBL] [Abstract][Full Text] [Related]
20. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Nurden AT; Viallard JF; Nurden P Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]